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Abstract
Objective The objective of our study was to examine the
management of the interaction between acenocoumarol or
phenprocoumon and several antibiotics by anticoagulation
clinics and to compare the consequences of this interaction on
users of co-trimoxazole with those for users of other antibiotics.
Methods A follow-up study was conducted at four anti-
coagulation clinics in The Netherlands. Data on measure-
ments of the International Normalised Ratio (INR),
application of a preventive dose reduction (PDR) of the
coumarin anticoagulant, fever and time within or outside
the therapeutic INR range were collected.
Results The study cohort consisted of 326 subjects. A PDR
was given more often to users of co-trimoxazole PDR than
to users of other antibiotics. The PDR in co-trimoxazole
users resulted in a significantly reduced risk of both
moderate overanticoagulation (INR >4.5) and severe over-
anticoagulation (INR >6.0) compared with no PDR, with
odds ratios (ORs) of 0.06 [95% confidence interval (CI):
0.01–0.51] and 0.09 (95% CI: 0.01–0.92), respectively. In
co-trimoxazole users without PDR, the risk of overanticoa-
gulation was significantly increased compared with users of
other antibiotics. All co-trimoxazole users spent signifi-
cantly more time under the therapeutic INR range during
the first 6 weeks after the course than users of other
antibiotics.
Conclusion PDR is effective in preventing overanticoagu-
lation in co-trimoxazole users, but results in a significantly
prolonged period of underanticoagulation after the course.
Avoidance of concomitant use of co-trimoxazole with
acenocoumarol or phenprocoumon seems to be a safer
approach than management of the interaction between these
drugs.
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Introduction
Coumarin-type anticoagulants have a narrow therapeutic
range. One important aspect of their safety is their
sensitivity to drug interactions, many of which have been
described [9, 11].
There are several reasons why antibiotic use can be
considered to be indicative of a change in anticoagulation
status in users of coumarin-type anticoagulants. When the
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with overanticoagulation [5, 12]. In two studies on the
interaction between coumarin anticoagulants and antibi-
otics, the risk of severe overanticoagulation, defined as an
International Normalised Ratio (INR) ≥6.0, was increased
more in users of sulfamethoxazole-trimethoprim (co-
trimoxazole) than in users of other antibiotics [12, 21].
Sulfamethoxazole is a strong inhibitor of CYP2C9 [24],
the main liver enzyme involved in the metabolism of
warfarin [13], acenocoumarol [19] and probably phenpro-
coumon [20], which could explain this stronger associa-
tion with overanticoagulation. Current clinical guidelines
in The Netherlands for the management of coumarin drug
interactions advise healthcare givers to avoid prescribing
the concurrent use of co-trimoxazole and coumarins [1].
Nevertheless, in daily practice co-trimoxazole is frequent-
ly prescribed to users of coumarins, since physicians in
anticoagulation clinics assume that an interaction with co-
trimoxazole can be managed in a manner similar to those
used to manage interactions that arise with the concurrent
use of coumarins with other antibiotics. An anticoagula-
tion clinic will initiate one of the following procedures
once it has been notified of the initiation of the use of an
antibiotic: (1) measurement of the INR during the antibiotic
course and adjustment of the coumarin dose depending on
the INR value (a reactive dose-adjustment); (2) a preven-
tive (coumarin) dose reduction (PDR) preceding an INR
measurement during or after the antibiotic course, assum-
ing that use of an antibiotic or the intercurrent infection
itself increases the risk of overanticoagulation. The PDR
approach seems even more relevant to co-trimoxazole than
to other antibiotics because the CYP2C9-inhibiting effect
of the former might increase the risk of overanticoagula-
tion more than the infectious state alone. However, PDR
could also lead to temporary undertreatment, and evidence
for the effectiveness of this approach is currently lacking.
There are no official guidelines for such dose adjustments,
and the application of PDR strongly depends on the
personal view of the responsible physician.
The aim of the present study was to examine the
management of the interaction between coumarin anti-
coagulants and antibiotics by anticoagulation clinics and its
consequences for users of co-trimoxazole and other anti-
biotics. To this end, we conducted a prospective follow-up
study at four anticoagulation clinics in The Netherlands.
Materials and methods
Study design
This was a follow-up study conducted at four anticoagula-
tion clinics in The Netherlands. We included patients who
were stabilised on one of the coumarin anticoagulants
acenocoumarol or phenprocoumon and who had started
using one of the following antibiotics between January
2001 and October 2003: co-trimoxazole, amoxicillin,
amoxicillin-clavulanic acid, clarithromycin, doxycyclin,
nitrofurantoin, norfloxacin or trimethoprim. In addition to
co-trimoxazole, we chose the other antibiotics based on
their use for the same kind of infections, mainly those of
the urinary and respiratory tract.
The subjects included in our study were prospectively
followed during the antibiotic course until the last INR
measurement, which occurred within 6 weeks following the
starting date of the antibiotic (follow-up time). We did not
intervene in the daily routine of the participating anti-
coagulation clinics and, in particular, we made no agree-
ments on checking the INR of patients during the antibiotic
course, on making additional INR measurements, on the
time intervals between INR measurements after the antibi-
otic courses or on dose adjustments when antibiotics were
prescribed. To assess the consequences of interaction
management reliably and to avoid confounding by an
unstable anticoagulation status preceding the antibiotic
course, we only included stabilised patients in our study.
Criteria for the assessment of stability were: (1) use of the
coumarin anticoagulant for at least 50 days before initiation
of the antibiotic; (2) availability of at least four INR
measurements before the initiation of the antibiotic; (3) the
last two INR measurements before initiation of the
antibiotic were within the therapeutic range; (4) a maxim
of one out of the last four INR measurements or a maxim of
30% of the INR measurements during the 50 days
immediately preceding initiation of the antibiotic were
outside of the therapeutic range, with no INR being above
5.5. Similar criteria for stability have been used in other
studies [12, 21].
We excluded subjects from our analyses in whom the
INR was not measured during the course of the antibiotic
and who used the antibiotic for a period shorter than 3 days
and longer than 14 days. If the INR was not measured
during the course, an interaction effect of the antibiotic
could be missed. Antibiotics used for less than 3 days or
more than 14 days are usually prescribed for prophylaxis
not for acute infections.
All patients were informed of the aims of the study and
were asked for their written consent to participate in the
study.
Setting and attitudes of anticoagulation clinics
on antibiotic use
All anticoagulation clinics in The Netherlands monitor the
INR in outpatients at a frequency varying from a few days
to maximally 6 weeks. The two target therapeutic ranges
336 Eur J Clin Pharmacol (2007) 63:335–343are the normal therapeutic range (INR: 2.0–3.5) and the
high therapeutic range (INR: 2.5–4.0).
The initiation of the use of an antibiotic is usually
reported to the anticoagulation clinics by the patients, their
pharmacists and/or the prescribing physicians.
The four anticoagulation clinics participating in this
study had different attitudes on the management of the
interaction between coumarins and antibiotics. The ap-
proach of three of the anticoagulation clinics was to
decrease the coumarin dose preventively if co-trimoxazole
was prescribed; one of the anticoagulation clinics applied a
PDR of 20–25% in the case of co-trimoxazole use. If one of
the other antibiotics examined in this study was prescribed,
the application of a PDR would depend on the seriousness
of the disease and on the occurrence of fever. The fourth
anticoagulation clinic had no established protocols for dose
reduction but indicated that it would monitor the INR of
every user of co-trimoxazole within 3–5 days after initiation
of the course.
Data collection
We collected relevant data on the participating patients and
recorded these in a database: sex and age of patient; dosage
and indication of the coumarin; prescribed antibiotics
(indication, dosage and duration of use); results of INR
measurements before, during and after the antibiotic course;
co-medication; relevant co-morbidities (malignancies, thy-
roid diseases, heart failure). These data were retrieved from
the medical files of the anticoagulation clinics. Patients
were asked to indicate on a questionnaire for which
infection the antibiotic was prescribed and whether they
had suffered from fever during the antibiotic course. We
recorded this as fever yes/no in our database. If the
coumarin-dose was reduced as soon as the antibiotic was
started in the absence of an actual INR, we recorded this as
a preventive dose-reduction and calculated the percentage
of the dose reduction from the data on dosage in the file of
the anticoagulation clinic.
In order to assess the anticoagulation status shortly after
the antibiotic course, we recorded the time spent within,
above and under the therapeutic range from the starting date
of the antibiotic until the last INR measurement within
6 weeks following the starting date of the antibiotic. Six
weeks is the maximal period between two INR measure-
ments if a patient is well stabilised. Furthermore, after a
longer follow-up period, differences between patients could
be more attributable to other factors than to the infection or
antibiotic use. If after the first INR during the antibiotic
course no second INR measurement was available within
the 6-week period after the starting date of the antibiotic,
we recorded no follow-up time and no time spent within,
above or under the therapeutic range.
Outcomes
The end points of our study were chosen to assess the
effectiveness of the management of the interaction between
coumarin anticoagulants and co-trimoxazole and other
antibiotics.
We examined the following parameters in users of co-
trimoxazole with and without PDR as well as in users of
other antibiotics with and without PDR:
1. occurrence of moderate overanticoagulation (INR >4.5)
and severe overanticoagulation (INR >6.0);
2. time spent within, above and under the therapeutic INR
range from the starting date of the antibiotic until the
last INR measurement within 6 weeks following the
starting date of the antibiotic.
Calculations and statistical analysis
We assessed the effects of the PDR within the group of
users of co-trimoxazole and within the group of users of
other antibiotics by comparing the occurrence of over-
anticoagulation in patients for whom a PDR had been
applied with the occurrence of overanticoagulation in
patients for whom PDR had not been applied (logistic
regression models). We also compared the occurrence of
overanticoagulation and time spent within, under and above
the therapeutic range of co-trimoxazole users with users of
other antibiotics (reference group). These comparisons were
made for patients with PDR and for patients without PDR.
Finally, we compared the time spent within, under and
above the therapeutic range in patients for whom a PDR
had been applied with those for whom a PDR had not been
applied (reference) within the groups of co-trimoxazole
users and users of other antibiotics (linear regression
models). In all models we adjusted for the potential
confounding covariates sex, age, target therapeutic range
and fever, as indicated by the patient. Covariates were
added to the statistical models one at a time. We adjusted
for a covariate if it changed the point estimation of the
outcome of interest by 5% or more upon inclusion in the
model.
Time spent within, above and under the therapeutic INR
range was calculated by the step-up method described by
Rosendaal et al. [15].
Although all patients were stable when they were
included in our study, we re-analysed our statistically
significant outcomes after excluding patients in whom
destabilisation could be due to factors other than those of
infection and/or fever (presence of thyroid disease, malig-
nancy or use of other enzyme-inhibiting or-inducing drugs).
All statistical analyses were performed with the statisti-
cal software package SPSS ver. 12 (SPSS, Chicago, Ill.).
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A total of 424 patients who met the inclusion criteria gave
their informed consent to participate in our study. Of these
patients, 81 did not have assesment of the INR during the
antibiotic course, 14 used the antibiotic for less than 3 days,
and 3 used the antibiotic for more than 14 days.
A PDR was applied more frequently for users of co-
trimoxazole (28/43; 65%) than for users of other antibiotics
(60/283; 21.2%) (Table 1).
The PDR applied was significantly greater in users of
co-trimoxazole than in users of other antibiotics (15.0 and
10.3%, respectively; P value for difference: 0.036; two-
sided t-test). The number of INR measurements during
follow-up was significantly higher in both users of co-
trimoxazole (PDR applied and PDR not applied) and users
of other antibiotics (PDR applied) than in users of other
antibiotics in whom a PDR was not applied. (P values of
0.028, 0.006 and 0.007, respectively; two-sided t-test).
Mean daily dosages for acenocoumarol were lower in
users of co-trimoxazole than in users of other antibiotics,
but this difference was not statistically significant and
even smaller (0.14 mg) after adjustment for differences in
age (Table 1).
In co-trimoxazole users, the PDR protected strongly
against both moderate and severe overanticoagulation
[adjusted odds ratio (OR): 0.06, 95% confidence interval
(CI): 0.01–0.51 for INR >4.5; adjusted OR: 0.09, 95% CI:
0.01–0.92 for INR >6]. For other antibiotics, the effect of
the PDR on overanticoagulation was not as strong and not
statistically significant (Tables 2 and 3).
If PDR was applied, the risk of overanticoagulation was
not increased in users of co-trimoxazole compared with
users of other antibiotics. However, if PDR was not
applied, there was a strongly increased risk of moderate
as well as severe overanticoagulation in co-trimoxazole
users compared with users of other antibiotics (adjusted
OR: 3.96, 95% CI: 1.33–11.8 for INR >4.5; adjusted OR:
3.86, 95%CI: 1.03–14.6 for INR >6.0) (Tables 2 and 3).
During the 6-week follow-up, co-trimoxazole users with
a PDR spent more time within and less time under the
therapeutic range than co-trimoxazole users without a PDR,
but these differences were not statistically significant. Users
of co-trimoxazole without a PDR spent significantly less
time within the therapeutic range than users of other
antibiotics with a PDR, whereas significantly more time
was spent under the therapeutic range. Moreover, co-
trimixazole users with a PDR also spent significantly more
time under the therapeutic range than did all users of other
Table 1 Characteristics of patients (n = 326) using antibiotics, treated by four anticoagulation clinics
Characteristic Co-trimoxazole (n=43) Other antibiotics
a (n=283)
PDR+
b (n=28) PDR-
c (n=15) PDR+
b (n=60) PDR-
c (n=223)
Men, no. (%) 22 (78.6) 10 (66.7) 30 (50.0) 114 (51.1)
Age in years, mean (SD) 75.4 (10.9) 75.1 (8.2) 72.6 (10.9) 71.4 (11.2)
Users of acenocoumarol, no. (%) 24 (85.7) 10 (66.7) 52 (86.7) 169 (75.8)
Follow-up time, mean (SD) 33.2 (5.6) 28.9 (8.0) 30.4 (7.2) 30.2 (7.2)
Fever, no. (%) 18 (64.3) 6 (40.0) 27 (45.0) 120 (53.8)
Normal target therapeutic range, no. (%)
d 19 (67.9) 5 (33.3) 30 (50.0) 112 (50.2)
Respiratory infections, no. (%) 8 (28.6) 3 (20.0) 33 (55.0) 116 (52.0)
Urinary tract infections, no. (%) 13 (46.4) 8 (53.3) 11 (18.3) 53 (23.8)
Malignancies, no. (%) 1 (3.6) 3 (20.0) 3 (5.0) 9 (4.0)
Thyroid diseases, no. (%) 0 0 1 (1.7) 11 (4.9)
Users of inhibiting drugs, no. (%) 0 1 (6.7) 5 (8.3) 17 (7.6)
Users of inducing drugs, no. (%) 1 (3.6) 0 1 (1.7) 4 (1.8)
INR measurements, mean no. (SD) 3.5 (0.9) 3.9 (1.5) 3.5 (1.1) 3.1 (1.1)
Acenocoumarol, mean dose, mg/day (SD) 2.42 (1.26) 2.41 (1.41) 2.61 (1.06) 2.60 (1.12)
Percentage PDR applied, mean (SD) in acenocoumarol users 15.0 (7.6) 10.3 (11.1)
Phenprocoumon, mean dose, mg/day (SD) 2.81 (0.86) 2.53 (1.02) 2.99 (1.31) 2.36 (1.00)
Percentage PDR applied, mean (SD) in phenprocoumon users 17.9 (15.8) 11.4 (7.0)
Percentage PDR applied, all coumarins, mean (SD) 15.4 (8.8) 10.5 (10.6)
aOther antibiotics: Trimethoprim (n=3), doxycyclin (n=104), amoxicillin (n=77), amoxicillin-clavulanic acid (n=36), clarithromycin (n=14),
norfloxacin (n=33), nitrofurantoin (n=16)
bPDR+, Preventive dose reduction applied
cPDR-, Preventive dose reduction not applied
dNormal target therapeutic range: INR 2.0–3.5
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12.9) (Tables 2 and 4).
Co-trimoxazole users with more than a 20% PDR spent
significantly more time under the therapeutic range than users
ofotherantibiotics(adjustedmeandifference:7.4mg;95%CI:
0.9–14.0; P=0.027). If less than a 20% PDR was applied, the
difference between the users of co-trimoxazole and those of
other antibiotics shrunk and was no longer significant.
The application of a PDR differed between anticoagula-
tion clinics. Three of the four anticoagulation clinics
Table 3 Odds ratios for effect of preventive dose reduction (PDR) and for (severe) overanticoagulation in users of co-trimoxazole compared with
users of other antibiotics
Odds ratios (95%CI) P Adjusted Odds ratios (95% CI)
a P
Effect of PDR on overanticoagulation
b
Co-trimoxazole
PDR applied, INR >4.5 0.10 (0.02–0.50) 0.005* 0.06 (0.01–0.51) 0.010*
PDR applied, INR >6.0 0.10 (0.01–1.02) 0.051 0.09 (0.01–0.92)
c 0.042*
PDR not applied Reference Reference
Other antibiotics
PDR applied, INR >4.5 0.70 (0.32–1.52) 0.37 N.A.
d
PDR applied, INR >6.0 1.36 (0.47–3.93) 0.57 N.A
PDR not applied Reference
Risk of overanticoagulation
PDR not applied
Co-trimoxazole, INR >4.5 4.52 (1.56–13.1) 0.006* 3.96 (1.33–11.8) 0.013*
Co-trimoxazole, INR >6.0 5.43 (1.53–19.2) 0.009* 3.86 (1.03–14.6) 0.046*
Other antibiotics Reference Reference
PDR applied
Co-trimoxazole, INR >4.5 0.68 (0.17–2.73) 0.59 N.A.
Co-trimoxazole, INR >6.0 0.41 (0.04–3.66) 0.42 0.30 (0.03–3.05)
e 0.30
Other antibiotics Reference Reference
*Statistically significant difference at P≤0.05
aAdjusted for differences in fever as indicated by patient, age, sex, target therapeutic range, unless otherwise indicated
bPDR, Preventive dose reduction
cAdjusted for differences in age and sex
dN.A., Adjustment not applied because the inclusion of covariates in our model did not result in a change of at least 5% in the odds ratios (see
text)
eAdjusted for differences in age, sex and fever as indicated by patient
Table 2 Occurrence of overanticoagulation and time spent within, above and under the therapeutic range by patients using co-trimoxazole and
other antibiotics
a
Outcome Co-trimoxazole Other antibiotics
PDR+
b (n=28) PDR-
b (n=15) PDR+
b (n=60) PDR-
b (n=223)
INR >4.5, no. (%) 3 (10.7) 25 (89.3) 9 (15.0) 45 (20.2)
d
INR > 6.0, no. (%) 1 (3.6) 4 (26.7) 5 (8.3) 14 (6.3)
e
Time within therapeutic range, mean % (95%CI)
c 71.1 (60.4–81.8) 51.8 (34.6–69.0) 76.2 (69.5–82.9) 75.7 (72.2–79.3)
f
Time above therapeutic range, mean % (95%CI) 15.0 (5.7–24.3) 20.3 (10.7–29.8) 12.3 (6.8–17.7) 18.9 (15.5–22.2)
g
Time under therapeutic range, mean % (95%CI) 14.0 (5.6–22.2) 27.9 (7.7–48.1) 11.5 (6.9–16.1) 5.4 (3.7–7.2)
h
a Calculated for the time from the date the antibiotic was first taken until the last INR measurement within 6 weeks following the starting date of
the antibiotic. Time within, above and under therapeutic range was calculated for antibiotic users in whom at least one INR measurement had
been performed within 6 weeks after the INR measurement during the antibiotic course. This resulted in the exclusion from the analysis of the
following number of subjects: co-trimoxazole (1 1); other antibiotics 14 (1 13). The numbers in parenthesis indicate the number of subjects with a
PDR and those without a PDR, respectively.
bPDR+, Preventive dose reduction applied; PDR-, preventive dose reduction not applied.
c95% CI, 95% Confidence interval for the reported mean value
dRange: 7.1% for nitrofurantoin to 27.6% for norfloxacin
eRange: 0% for nitrofurantoin and trimethoprim to 8.6% for doxycyclin
fRange: 71.8% for amoxicillin to 84.8% for norfloxacin
gRange: 8.6% for norfloxacin to 22.0% for amoxicillin
hRange: 3.3% for norfloxacin to 11.1% for clarithromycin
Eur J Clin Pharmacol (2007) 63:335–343 339participating in this study applied PDR as a rule in co-
trimoxazole users (83.3–85.7%). In terms of users of other
antibiotics, the application of a PDR was more varied: in
three of the anticoagulation clinics PDR was sometimes
applied (in 17.6–50.8% of all cases), whereas one anti-
coagulation clinic did not apply the PDR approach at all.
The overall percentage of time spent within the therapeutic
range during the first 6 weeks after initiation of an
antibiotic ranged from 73.7 to 78.0% at all four anti-
coagulation clinics. In the anticoagulation clinic that did not
apply a PDR, overanticoagulation (INR>4.5) occurred most
frequently for the all antibiotics class (26.9 vs.10.8–22.7%
in the other clinics), with the difference being most marked
for co-trimoxazole (54.4 vs. 14.3–16.7% in the other
clinics).
We also analysed our data separately for users of
acenocoumarol and phenprocoumon. There were no differ-
ences in the point estimates of most of our main outcomes
between users of either of these coumarins, with the
exception of percentage of time spent under the therapeutic
range in phenprocoumon users for whom PDR was applied.
However, most of the results that were statistically
significant for all coumarin users were also significant for
users of acenocoumarol (n=252; 78.2 %), whereas they
were in most cases not significant for the smaller group of
users of phenprocoumon (n=71; 21.8%) (Table 5).
Re-analysis of our results after excluding patients with
thyroid diseases and malignancy or those using enzyme-
inhibiting or -inducing drugs gave similar point estimates or
trends, significance for severe overanticoagulation in users
of co-trimoxazole compared to other antibiotics and for
time spent within the therapeutic range for users of co-
trimoxazole in whom PDR was not applied (data not
shown).
Table 4 Comparisons of time spent within, under and above the therapeutic range by users of co-trimoxazole and other antibiotics
a
Mean difference P Adjusted mean difference
b P
PDR applied
Co-trimoxazole, % time within TR
c −5.1 (−17.2 to 6.9) 0.40 −4.2 (−17.1 to 8.6) 0.51
Co-trimoxazole, % time above TR 2.7 (−7.3 to 12.7) 0.60 1.9 (−8.9 to 12.7) 0.73
Co-trimoxazole, % time under TR 2.4 (−6.3 to 11.1) 0.58 N.A.
d
Other antibiotics Reference Reference
PDR not applied
Co-trimoxazole, % time within TR −23.8 (−38.2 to –9.6) < 0.001* −22.3 (−36.6 to –8.0)
e 0.002*
Co-trimoxazole, % time above TR 1.4 (−11.7 to 14.5) 0.83 N.A.
Co-trimoxazole, % time under TR 22.5 (14.4 to 30.6) < 0.001* 20.4 (12.4 to 28.5)
f < 0.001*
Other antibiotics Reference Reference
Co-trimoxazole
PDR applied, % time within TR 19.3 (0.7 to 37.9) 0.042* 14.6 (−5.8 to 35.1)
f 0.16
PDR applied, % time above TR −5.3 (−19.6 to 9.0) 0.46 −4.4 (−19.1 to 10.3)
g 0.55
PDR applied, % time under TR −14.0 (−31.6 to 3.6) 0.16 −10.7 (−29.0 to 7.5)
g 0.24
PDR not applied Reference Reference
Other antibiotics
PDR applied, % time within TR 0.5 (−7.0 to 8.1) 0.89 0.6 (−6.8 to 8.2) 0.87
PDR applied, % time above TR −6.6 (−13.5 to 0.3) 0.061 N.A.
PDR applied, % time under TR 6.1 (2.0 to 10.1) 0.003* N.A.
PDR not applied Reference Reference
Co-trimoxazole, PDR applied
% time within TR −4.7 (−15.1 to 5.6) 0.37 −3.0 (−13.5 to 7.5)
f 0.58
% time above TR −2.4 (−11.9 to 7.1) 0.61 −3.7 (−13.3 to 6.0)
h 0.46
% time under TR 7.2 (1.2 to 13.1) 0.018* 6.9 (1.0 to 12.9)
h 0.022*
Other antibiotics
PDR applied + PDR not applied Reference Reference
*Statistically significant difference at P≤0.05
aCalculated for the time from the starting date of the antibiotic until the last INR measurement within 6 weeks following the starting date of the
antibiotic.
bAdjusted for differences in fever as indicated by patient, age, sex, target therapeutic range, unless otherwise indicated.
cTR, Therapeutic range;
dN.A., Adjustment not applied because including covariates in our model did not result in a change of at least 5 % of mean difference (see text).
eAdjusted for differences in sex.
fAdjusted for differences in sex and target therapeutic range.
gAdjusted for differences in age, sex and target therapeutic range.
hAdjusted for differences in sex, target therapeutic range and fever as indicated by patients.
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The results of the present study, in which we evaluated the
management of the interaction between antibiotics and
coumarin anticoagulants by anticoagulation clinics, dem-
onstrated that a PDR reduces the risk of overanticoagula-
tion in co-trimoxazole users to the level of other antibiotic
users, but also that management of the interaction between
coumarins and co-trimoxazole results in a significantly
longer period of undertreatment during the first 6 weeks
after initiation of the antibiotic.
In three of the four anticoagulation clinics PDR was
applied more frequently and was significantly higher in
users of co-trimoxazole than in users of other antibiotics,
indicating that anticoagulation clinics are aware of the
seriousness of the interaction between coumarins and co-
trimoxazole. In the cases and case series that have reported
on overanticoagulation and bleeding with the concurrent
use of antibiotics and co-trimoxazole [2, 3, 6–8, 10]a n
effect of the intercurrent infection on the anticoagulation
status could not be ruled out. However, Penning-van Beest
et al. (case control study) and Visser et al. (follow-up study)
both demonstrated that an increased risk of severe over-
anticoagulation (INR >6.0) was particularly associated with
co-trimoxazole [12, 21]. A plausible explanation is the
strong inhibition of the main metabolising enzyme,
CYP2C9, of the coumarins by sulfamethoxazole, the
sulphonamide component of co-trimoxazole [24].
Although PDRs as applied in clinical practice are
effective in reducing the overanticoagulation risk in co-
trimoxazole users, the price that has to be paid for the
concurrent use of co-trimoxazole is a significantly pro-
longed period of underanticoagulation compared with the
use of other antibiotics during the first 6 weeks after the
antibiotic course. This difference was more marked in
the subgroup of subjects in whom PDR was not applied.
Possible explanations for this result are (1) the usually
shorter time span between PDR and the first INR
measurement (always within the course) compared to
the time span between a reactive dose reduction
following supratherapeutic INR and subsequent INR
measurement (usually after the course) and (2) the higher
reactive dose reduction which is applied in the case of
severe overanticoagulation (INR >6.0). However, even
co-trimoxazole users for whom the PDR had been applied
had a significantly prolonged period of underanticoagulation
compared with all of the users of other antibiotics (PDR
applied and PDR not applied taken together). This last
comparison is totally logical because our results strongly
suggest that a PDR should always be applied in co-
trimoxazole users, whereas this is as a rule not required in
users of other antibiotics. The adjusted difference in time
spent under the therapeutic range – ranging from 6.9 (PDR
applied) to 22.5% (PDR not applied) – corresponds to about
2–7 days of the mean follow-up time of 30 days in otherwise
stabilised patients; this time interval is clinically relevant and
can be avoided by substituting co-trimoxazole.
It is not difficult to explain the prolonged period of
underanticoagulation in co-trimoxazole users. The ap-
plication of a PDR, which was in this study higher in
Table 5 Main outcomes stratified for users of acenocoumarol and phenprocoumon
Outcome Acenocoumarol (n=254) Phenprocoumon (n=71)
Protective effect of PDR Adjusted OR (95%CI)
a P Adjusted OR (95%CI)
a P
Co-trimoxazole
PDR applied, INR >4.5 0.08 (0.01–0.70) 0.022* 0.16 (0.01–4.48) >0.3
b
PDR not applied Reference Reference
Risk of overanticoagulation
PDR not applied
Co-trimoxazole, INR >4.5 4.40 (1.15–16.8) 0.030* 3.83 (0.55–26.7) 0.18
Other antibiotics Reference Reference
% Time within or under TR Mean difference (95%CI) Mean difference (95%CI)
Co-trimoxazole, % time within TR −22.1 (−39.1 to –5.0) 0.011* −21.4 (−49.4 to 6.6) 0.13
Co-trimoxazole, % time under TR 20.3 (10.9–29.7) <0.001* 22.6 (5.7–39.5) 0.010*
Other antibiotics Reference Reference
Co-trimoxazole, PDR applied
% time under TR 9.1 (3.0–15.1) 0.004* −6.7 (−23.0 to 9.6) 0.42
Other antibiotics
PDR applied + PDR not applied Reference Reference
*Statistically significant difference at P≤0.05
aAdjusted for differences in fever as indicated by patient, age, sex and target therapeutic range
bAdjustment not applied because the number of patients with INR >4.5 was zero; OR was calculated by increasing the values of each of the cells
of the crosstable by 0.5
Eur J Clin Pharmacol (2007) 63:335–343 341co-trimoxazole users, might overcompensate for over-
anticoagulation, whereas the reactive dose reduction
following overanticoagulation carries the same risk of
overcompensation and undertreatment as PDR. Conse-
quently, the inhibition of CYP2C9 by co-trimoxazole
superimposes an additional problem upon the already
potentially destabilising effects of the infection and fever.
Because our results for acenocoumarol in the separate
analyses were predominantly in agreement with the
overall results, our findings primarily apply to acenocou-
marol users. It is possible that users of phenprocoumon
are less sensitive to interactions with CYP2C9 inhibitors
such as co-trimoxazole [20, 22]. We do expect that our
results also apply to users of warfarin, which seems to be
even more CYP2C9 sensitive than acenocoumarol [18].
Our study has several limitations. Because we retrieved
medical data from anticoagulation clinics, it is possible that
not all of the relevant data on potentially destabilising
factors, such as malignancies, thyroid diseases and the use
of other inhibitors of coumarin metabolism, were available.
However, by only including patients who were obviously
stable at the moment of initiation of the antibiotic, we
decreased the chance that such factors changed the
anticoagulant status during the antibiotic course. A second
limitation is the absence of data on the presence of
polymorphisms of the genes encoding the coumarin-metab-
olising enzyme CYP2C9 or the pharmacodynamic target of
coumarins, VKORC1. The genotypes of both CYP2C9 [16,
22] and VKORC1 are strongly associated with interindivid-
ual variability in coumarin dose requirements [4, 14, 17,
23]. Further studies would be needed to assess whether the
risk of overanticoagulation in co-trimoxazole users differs
between carriers of a CYP2C9 or VKORC1 polymorphism
and wild-type patients. It should be clear that our results
only apply to patients with a stabilised anticoagulation state
at the initiation of the antibiotic course.
In conclusion, if co-trimoxazole is prescribed to users of
coumarin anticoagulants, the interaction can be managed by
applying PDR, which adequately decreases the risk of
overanticoagulation, but this successful management comes
at the cost of a prolonged period of underanticoagulation after
the course. Consequently, rather than managing the interac-
tion it is better to avoid prescribing co-trimoxazole as a
therapeutically equivalent alternative is always available.
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